RxDoctor Payments Data

Lisa Jennings

Acute Care · Kansas City, MONPI 1013248004

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,600 of the $3,816 with a category attached, or 68.1%. 7 manufacturers reported payments, led by Scpharmaceuticals Inc. at 46.3% of the total. 2025 is the largest year on record at $2,179, more than ten times the $20 reported in 2021. Among acute care clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,816in general payments, 2019–2025

Across 16 payments — averaging $238.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scpharmaceuticals Inc.$2K
  • Boston Scientific$1K
  • Abbott$204
  • Cvrx, Inc.$173
  • Novartis$169
  • Impulse Dynamics (USA) Inc.$157
  • plus $137 from 1 others

What the payments were for

  • Speaking & faculty fees$2,60068%
  • Food & beverage$1,21632%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,816 in reported general payments places this provider in the 90th percentile of 272 acute care providers in Missouri.

See all acute care providers in Missouri

Medicare billing

Part B allowed, 2024
$32,934
Medicare patients
180
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan42$63,264
JardianceEmpagliflozin36$52,967
EliquisApixaban29$37,650
FarxigaDapagliflozin Propanediol23$31,826
XareltoRivaroxaban20$16,015
OzempicSemaglutide13$12,601
Eplerenone29$2,401
Torsemide70$2,045
Metoprolol Succinate111$1,696
Bumetanide12$800
Potassium Chloride34$764
Atorvastatin Calcium57$697
Spironolactone76$605
Valsartan13$532
Pantoprazole Sodium34$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$169$63,26442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 272 acute care providers in Missouri.

Other acute care in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →